abbv-706
mAbexperimentalADC
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Dec 5, 2022 (NCT05599984)
Timeline
Indications
Mechanism of action
- Seizure protein 6 homologBINDING AGENT
binding agent - SEZ6
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07155174 | Phase 2/Phase 3 (Phase 3) | Dec 6, 2025 | AbbVie |
| NCT05599984 | Phase 1 | Dec 5, 2022 | AbbVie |
| NCT07310277 | N/A | — | AbbVie |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 3 | 3 | 3 | 2022 |
1 organizations
Page 1 / 1